UPDATED: Sarepta shares crash on a harsh FDA review of Duchenne’s drug

John Carroll

's quest to gain an accelerated approval for eteplirsen was subjected to some scrutiny by regulators at the FDA. And the insiders concluded that much of the data submitted for an approval was a mess, with weak, inconsistent data raising serious questions about the efficacy of the .

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS